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A B S T R A C T
Typhoid vaccines based on protein-conjugated capsular Vi polysaccharide (TCVs) prevent typhoid in infants and
young children. Analysis of the serum anti-Vi IgG response following immunisation against typhoid confirms the
immunogenicity of TCVs and forms an important part of the pathway to licensing. Comparative studies could
expedite the licencing process, and the availability of a standardised ELISA method alongside the 1st
International Standard (IS) 16/138 for anti-typhoid capsular Vi polysaccharide IgG (human) will facilitate this
process. To this end, a non-commercial ELISA based on a coat of Vi and poly-L-lysine (Vi-PLL ELISA) was
evaluated by 10 laboratories. Eight serum samples, including IS 16/138, were tested in the standardised Vi-PLL
ELISA (n= 10), a commercial Vi ELISA (n = 3) and a biotinylated Vi ELISA (n= 1). Valid estimates of potencies
relative to IS 16/138 were obtained for all samples in the Vi-PLL ELISA and the commercial ELISA, with good
repeatability and reproducibility evident from the study results and concordant estimates obtained by the two
ELISA methods. The study demonstrates that the Vi-PLL ELISA can be used in clinical trial studies to determine
the immunogenicity of TCVs.
1. Introduction
Typhoid fever is caused by an infection with Salmonella enterica
subspecies enterica serovar Typhi (S. typhi). In developing countries,
typhoid disease particularly affects children and infants and is a con-
siderable cause of morbidity and mortality. A recent study estimated a
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global incidence of 12 million cases of typhoid and 129,000 deaths each
year [1].
Capsular Vi polysaccharide (Vi) is a virulence factor of S. typhi and
considered a protective antigen in typhoid vaccines [2,3]. Vaccination
is the most cost-effective strategy to prevent and control typhoid fever
in endemic areas and in areas where anti-microbial resistant strains
reside. In the 1980s, oral live attenuated Ty21a and the injectable plain
Vi vaccines were licensed and have been on the market since. Un-
fortunately, these vaccines suffer two drawbacks: they are not suitable
for use in children under five and two years of age respectively, and
plain Vi vaccines are unable to induce a booster response in adults and
children, and for those at risk (e.g. lab workers) a repeat immunisation
is required every 3 years [4–6]. Conjugation of Vi to a carrier protein
such as a bacterial toxoid remedied these shortcomings: a prototype
typhoid conjugate vaccine (TCV) consisting of Vi conjugated to re-
combinant Pseudomonas aeruginosa exoprotein A was proven to be im-
munogenic and induced a booster response in young children, was safe
and efficacious in pre-school age children and infants and induced a
long lasting anti-Vi IgG response [7–9]. The success of this TCV
prompted the World Health Organization (WHO) to draft the WHO
guideline on the quality, safety and efficacy of TCVs, which provides a
framework to evaluate TCVs, compare clinical trial studies and analyse
the safety, consistency and potency of TCVs by physicochemical assays
and immunoassays [10,11].
Three TCVs consisting of Vi conjugated to tetanus toxoid (Vi-TT) are
licensed in India on the bases of immunogenicity and safety studies
[12–14]. Indeed, the presence of anti-Vi IgG following immunisation
with a Vi vaccine is considered a correlate of protection [7–9,11,15].
Studies in a controlled human infection model (CHIM), showed the Vi-
TT vaccine to have similar effectiveness compared with plain Vi vac-
cine, but with improved immunological properties [16]. Currently,
three TCVs are progressing through clinical trials, three are ap-
proaching licensure, and a further five are at the pre-clinical stage [14].
Recently, a phase III field trial in Nepal of Vi-TT showed it is efficacious
and reduces the incidence of S. typhi in children [17], and, in Hyder-
abad (Pakistan) a mass immunisation campaign with Vi-TT is under-
taken to control an outbreak of antimicrobial resistant variants [18].
To expedite the licensing process for new TCVs, we produced and
evaluated the first International Standard (IS) for anti-Vi IgG (human),
16/138 [19]. A collaborative study showed that performance of IS 16/
138, US reference reagent Vi-IgGR1, 2011 and individual post-im-
munisation sera was most consistent in the commercial VaccZyme
Human Anti-Salmonella typhi Vi IgG ELISA (Binding Site, UK) followed
by the Vi ELISA pre-coated with poly-L-lysine (Vi-PLL). The poor per-
formance of ELISAs based on a coat of Vi only was noted in this study,
its predecessor as well as an earlier study [19–21]. The latter ob-
servation agrees with previous studies that reported poor binding of
bacterial polysaccharides to the micro-plate surface resulting in
inconsistent ELISA results, which can be mitigated by pre- or co-coating
the polysaccharide with a protein or by chemical modification of the
polysaccharide [20,22,23]. Poly-L-lysine is a representative of nucleic
acid binding polymers and has been used to bind DNA and RNA avidly
on the basis of their charge and thus increase their adherence to the
solid phase [24]. Like these polymers, polysaccharides have a negative
charge and a PLL coating will capture these molecules efficiently. Poly-
L-lysine was chosen as co-coating protein over human serum albumin,
because the Vi PLL ELISA showed superior assay precision in a com-
parative study [19].
Following the establishment of IS 16/138, the WHO Expert
Committee on Biological Standardization (ECBS) requested a study in
order to establish whether a non-commercial Vi ELISA based on these
principles could be a reliable and robust alternative to the commercial
VaccZyme ELISA [25]. The current study was designed to evaluate the
Vi-PLL ELISA as a generic and non-commercial alternative to the
VaccZyme ELISA. The performance and reproducibility of the Vi-PLL
ELISA alongside the commercial VaccZyme ELISA was assessed by 10
laboratories, using a set of pre- and post-immunisation sera from vo-
lunteers immunized with licenced Vi vaccines, as described previously,
IS 16/138 and working standard 10/126 [19].
2. Materials and methods
2.1. Participating laboratories and assay codification
Ten participants, including vaccine manufacturers, national control
laboratories and research laboratories from seven countries tested the
study samples and supplied data for this study (see acknowledgments
section for details). Throughout the study, laboratories were identified
by a randomly assigned laboratory code number to maintain con-
fidentiality. Data were collected and analysed at NIBSC. A study pro-
tocol and the procedure for the Vi-PLL ELISA was sent to each parti-
cipant along with six suggested plate layouts to be used.
2.2. Samples used in the collaborative study
Each participant received a sample set comprising one ampoule of IS
16/138, coded ampoules (G to M), and one ampoule of 10/126. A brief
characterisation of the study samples, study codes, NIBSC codes and
their reactivity in the VaccZyme ELISA based on preliminary testing is
given in Table 1. Samples IS 16/138, 10/126 and coded samples G, I
and J had been used previously [19].
Coded samples and IS 16/138 were produced using sera donated by
volunteers immunized with WHO prequalified and licensed vaccines
either a plain Vi vaccine or a Vi-TT conjugate vaccine, who were re-
cruited by the Oxford Vaccine Group (OVG) [16,19]. Sera used for 10/
126, originated from clinical trial volunteers immunized with the same
Table 1
Characterisation of samples used in this study.
Approximate activity in VaccZyme ELISA NIBSC code Description
Kit controla IS 16/138
IS 16/138 NIBSC 16/138 Pooled anti-Vi IgG sera from 16 volunteers 631 EU mL−1b 100 IU mL−1b
10/126 NIBSC 10/126 Pooled anti-Vi IgG sera from 9 volunteers 842 EU mL−1b 109 IU mL−1b
G NIBSC 16/150 Post-Typbar TCV vaccination serum 350 EU mL−1b 38 IU mL−1b
H NIBSC 16/138 Pooled anti-Vi IgG sera from 16 volunteers 631 EU mL−1b 97 IU mL−1b
I NIBSC 16/144 Post-Typbar TCV vaccination serum 345 EU mL−1b 25 IU mL−1b
J NIBSC 16/146 Post-Typhim vaccination serum 524 EU mL−1b 62 IU mL−1b
K NIBSC 16/148 Post-Typhim vaccination serum 150 EU mL−1c –
L NIBSC 16/168 Post-Typbar TCV vaccination serum 3876 EU mL−1c –
M NIBSC 16/180 Post-Typhim vaccination serum 61 EU mL−1c –
a Supplied by manufacturer.
b Rijpkema et al. 2018.
c Preliminary estimate based on 2 VaccZyme ELISA runs performed at NIBSC.
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Vi-TT conjugate vaccine and sera were donated by Bharat Biotech
Limited International of India [19,20].
All samples tested negative for antibodies to HIV 1/2 and hepatitis C
and hepatitis B surface antigen. Freeze dried samples IS 16/138, 10/
126 and G to M were reconstituted as described in the instructions for
use.
To allow for a standardised Vi-PLL ELISA to be performed by par-
ticipants, each of them received essential reagents which met the de-
signated specifications of the assay: one ampoule of IS 12/244 for Vi
from Citrobacter freundii, one ampoule of mouse monoclonal anti-
human IgG Fc alkaline phosphatase (AP) conjugate, one vial of poly-L-
lysine and one vial of 4-nitrophenyl phosphate disodium salt hexahy-
drate substrate. In one instance, BRIJ-35 was supplied as well.
VaccZyme ELISA kits were sent to 3 participants. All samples and re-
agents were sent on dry ice or 2–8 °C as prescribed.
2.3. ELISAs
All participants tested the study samples in the Vi-PLL ELISA. In
addition, three participants used the VaccZyme ELISA and one parti-
cipant carried out an in-house biotinylated Vi ELISA. The code and a
brief description of the ELISAs are given in Table 2. ELISA procedures
are described below. Six different plate layouts were provided, and
samples were tested over two days with 3 plates on each day. Each
participant was asked to prepare starting dilutions of samples at 1:100
in appropriate assay diluents, except for IS 16/138, which had a
starting dilution of 1:25 and sample L which had a starting dilution of
1:400.
2.3.1. VaccZyme ELISA
The VaccZyme ELISA was carried out according to the manu-
facturer's instructions (Binding Site). The VaccZyme ELISA is based on
Vi of S. Typhi. Five calibrators, covering a range from 7.4, 22.2, 66.7,
200 and 600 EU mL−1, and a high and a low positive control were
included in each run. The assay has a sensitivity of 7.4 EU mL−1. Plates
were read at OD450nm.
2.3.2. Vi poly-L-lysine ELISA
The procedure for the Vi-PLL ELISA is a modification of the assay
described by Szu et al. [26] by the addition of a pre-coating step with
high molecular weight poly-L-lysine hydrobromide (P1399, Sigma)
[24,27], followed by a coat of Vi from C. freundii (NIBSC 12/244). In
brief, 100 μL of 10 μg poly-L-lysine mL−1 in PBS was added to wells of a
Nunc Maxisorp plate, incubated at RT for 2 h and washed 6x with
0.85% NaCl and 0.1% Brij35 in ultrapure water (NaCl-Brij 35), 100 μL
of 2 μg Vi mL−1 in PBS was added to the wells. Plates were incubated
overnight at 37 °C and washed 6x with NaCl-Brij 35. 250 μL 1% BSA in
PBS (Blocking Buffer, BB) was added to each well. Plates were in-
cubated for 1 h at 37 °C and washed six times. Dilutions of test samples
were prepared in assay diluent 1 (AD1: BB with 0.1% Brij35). 100 μL of
diluted tested sample was dispensed to appropriate wells of the plate.
Samples were incubated at 37 °C for 1 h, and washed 6x with NaCl-Brij
35. Then 100 μL of mouse monoclonal Anti-Human IgG Fc AP conjugate
diluted 1:5000 in AD1 was added to each well, incubated at 37 °C for
1 h and washed 6x with NaCl-Brij 35. 100 μL 4-Nitrophenyl Phosphate
disodium salt hexahydrate substrate (N 7653, Sigma) in Tris/3 mM Mg-
buffer (pH 9.8) was added per well and incubated at RT in dark for 1 h,
followed by the addition of 50 μL 3 M NaOH stop solution to each well.
The plate was read at OD405nm.
A post-study questionnaire revealed that participants adhered clo-
sely to the procedure described above (results not shown). However,
some variations occurred: plates were rinsed either by hand or by plate
washer, and if a plate washer is used a 180° turn of the plate after three
rinses should be carried out. Laboratories 1 and 10 sealed ELISA plates
during incubation steps but most laboratories covered plates with lids.
2.3.3. Biotinylated Vi ELISA
The procedure carried out by laboratory 6 is a minor modification of
the ELISA described by Ferry et al. [28]. The plate surface is coated
with streptavidin to capture biotinylated Vi from S. typhi (Fina Bioso-
lutions LLC). In brief, streptavidin from Streptomyces avidinii (Sigma,
S4762) was prepared in a solution of 3 μg mL−1 and 100 μL was added
to each well of flat bottom microtiter plates (Nunc Maxisorp) and in-
cubated uncovered at 37 °C overnight, allowing the solution to eva-
porate to dryness. Pre-coated plates were stored at 4 °C until used for
coating. For antigen coating, 2 μg mL−1 of biotinylated S. Typhi Vi PS
produced locally was prepared in PBS (pH 7.4) and 100 μL was added to
the wells of pre-treated plates. Plates were incubated for 3 h at 37 °C
and washed with PBS-T and wells were blocked overnight with 250 μL
PBS containing 10% non-fat dry milk at 4 °C. Plates were washed 6x
with PBS-T with 2 min soaking period in between washes. Sera and
reference reagents were diluted in AD2 (10% non-fat dry milk (w/v) in
PBS (pH 7.3–7.5) and 0.05% Tween-20) and added to the plates. All
plates were incubated for 1 h at 37 °C. Following incubation and
washing as described above, plates were incubated with HRP-labelled
goat anti-Human IgG (Jackson Immunoresearch, 109-035-008) diluted
in AD2 for 1 h at 37 °C. The plates were washed 6x with PBS-T, and
100 μl of TMB Microwell Peroxidase Substrate (KPL, SeraCare Life
Sciences Inc) was added to each well, incubating for 15 min in the dark
(with agitation). The reaction was stopped by adding 100 μL of 1 M
Phosphoric acid per well. Plates were read immediately at OD450nm.
2.4. Statistical analysis
Raw data from all individual plates were analysed with a four-
parameter logistic model (sigmoid curves) in order to determine the
potencies of study samples relative to IS 16/138. An example of the
data obtained from a single plate is shown in Fig. 1. Analysis was
performed using EDQM CombiStats Software Version 5.0 [29]. Accep-
table parallelism of dose-response relationships for a test sample and IS
16/138 was concluded if the slope ratio calculated by CombiStats was
within the range [0.80, 1.25]. Acceptable precision was concluded for
each relative potency estimate if it had a 95% confidence interval no
wider than 80–125% of the estimate. In addition to these criteria for
individual samples, each plate was only considered acceptable if valid
potency estimates were obtained for sample H (coded duplicate of IS
16/138) and 10/126, both within 66.7–150% of their assigned values
of 100 IU mL−1 and 109 IU mL−1 respectively. No potency estimates
have been reported where samples or plates did not meet these criteria.
It should be noted that the validity criteria were intended for use in the
analysis of data from this study only, in order to apply consistent cri-
teria to all laboratories and assess their relative performance. They
Table 2
Format of Vi ELISAs used by participants.
Laboratory code ELISA method Vi characteristics Antigen coating procedure
Name Format Status Biological origin
1,5,6, VaccZyme Indirect Not disclosed S. Typhi Procedure not disclosed
1,2,3,4,5,6,7,8,9,10 Vi poly-L-lysine Indirect Native C. freundii Pre-coat with poly–L-Lysine to bind Vi
6 Biotinylated Vi Capture Biotinylated S. Typhi Streptavidin coat to bind biotinylated Vi
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should not be interpreted as suitable for routine use in the assessment of
assay validity within the collaborating laboratories unless suitably
justified.
Data from laboratory 3 indicated IS 16/138 was not tested at the
appropriate requested dilutions, therefore potencies of study samples
relative to sample H, the coded duplicate of IS 16/138, were analysed
using a parallel line model. The same assay validity criteria as described
above were applied.
All mean results shown in this report are unweighted geometric
means (GM). Variability has been expressed using geometric coeffi-
cients of variation (GCV = {10s-1} × 100%, where s is the standard
deviation of the log10 transformed estimates). Individual assay esti-
mates of relative potency were log transformed and a mixed effects
model used to determine intra-laboratory and inter-laboratory variance
components (also expressed as % GCV) for each sample.
Further assessment of agreement in geometric mean results for each
pair of laboratories was performed by calculating Lin's concordance
correlation coefficient [30,31] with log transformed data. Calculations
for this were performed using the R package ‘DescTools’ [32]. A value
of 1 for this coefficient indicates perfect agreement between the two
laboratories.
3. Results
3.1. Performance of individual laboratories
The number of valid relative potency estimates obtained for each
sample in each laboratory are shown in Table 3 and cases where fewer
than three valid estimates were obtained are highlighted. The intra-
laboratory (between-plate) variability for each sample is shown in
Table 4 and cases where the GCV value exceeds 25% are highlighted.
Details of all individual assay results and outcomes are provided in the
supplementary table (attached separately). A summary of the causes of
assay invalidity when applying the criteria described above is given in
Table 5. A large number of the invalid assays (21 out of 53) were due to
the non-parallelism of sample K and IS 16/138 in Vi-PLL ELISAs, par-
ticularly those performed by laboratories 2, 3, 5 and 7, with slope ratios
for sample K falling below the acceptable lower limit of 0.80 (see
Fig. 2). This phenomenon appears to be unique for sample K and was
not observed for sample M which has a similar low relative potency.
Apart from this observation regarding sample K, the reasons for assay
invalidity are mixed (e.g. non-parallelism, 10/126 giving result higher
or lower than expected range) and related to the performance quality of
the laboratory.
If these criteria are used to define a good assay performance (i.e.
three or more valid estimates for all samples and GCV values ≤ 25%),
the Vi-PLL ELISA of laboratories 1, 2, 6, 8, 9, the VaccZyme ELISA of
laboratories 1 and 6, and the biotinylated Vi ELISA of laboratory 6 were
all considered to have been performed to a good standard.
Laboratories 3, 5 and 10 also appeared to perform the Vi-PLL ELISA
to an acceptable standard, obtaining three or more valid estimates for
all samples except for K. All GCV values for these laboratories were also
≤25%, with the exception of samples G and L by laboratory 5 (GCV
values of 27% and 28% respectively).
Several high GCV values (>40%) or a low number of valid esti-
mates were obtained by laboratories 4 and 7 for the Vi-PLL ELISA and
by laboratory 5 for the VaccZyme ELISA, therefore the quality of the
performances of these laboratories was considered doubtful for these
assays. Based on our assessment, the data from these laboratories were
excluded from further calculations to assess inter-laboratory variability
(reproducibility) and the comparison of the two ELISAs.
3.2. Comparison of Vi poly-L-lysine and VaccZyme ELISAs
Table 6 and Fig. 3 show the GM potency estimates in IU mL−1 for
each of the study samples as reported by each laboratory. Table 7 shows
the concordance correlation coefficients for each laboratory pair, with
values in excess 0.80, 0.90 and 0.95 shaded to indicate increasing levels
Fig. 1. Example of data reported for single Vi-PLL ELISA plate.
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of concordance in results obtained across the panel of samples tested in
the Vi-PLL and VaccZyme ELISAs. The majority of values for laboratory
2 were <0.80, showing poor concordance with other laboratories.
Excellent concordance was observed between laboratories 1, 3 and 8
performing the Vi-PLL ELISA and laboratories 1 and 6 performing the
VaccZyme ELISA (all values > 0.95). In addition, low intra-laboratory
variability was observed for these laboratories, with average GCV va-
lues < 10% (see Table 4).
A summary of overall GM potency estimates from each ELISA, ex-
cluding data from laboratory 2 for the Vi-PLL ELISA, is shown in Table 8
and Fig. 4a. An illustration of the highest levels of agreement and re-
producibility that can be achieved for the Vi-PLL and VaccZyme ELISAs
reached by laboratories which demonstrated a superior level of per-
formance in this study is given in Table 8 and Fig. 4b. A high degree of
concordance in geometric mean estimates was evident between the two
ELISA methods (Lin's concordance correlation coefficient 0.974 and
0.992 in Fig. 4a and b, respectively).
It was noted that samples G, I and J were tested in the previous
study to establish IS 16/138 [19]; and that the GM potency estimates
obtained by the VaccZyme ELISA in that study (38, 25 and 62 IU mL−1
for samples G, I and J, respectively; n = 6) show excellent agreement
with the geometric mean of values obtained by laboratories 1 and 6 in
this study (37, 25 and 63 IU mL−1 for samples G, I and J, respectively;
n = 2; Table 8). In the same study, geometric mean potencies were
obtained by the Vi-PLL ELISA for these samples (43, 27 and 67 IU mL−1
Table 3
Number of valid potency estimates relative to IS 16/138 obtained out of 6 runs for each study sample in the VaccZyme, Vi poly-L-lysine and biotinylated-Vi ELISAs.
ELISA Laboratory code Valid potency estimates per study sample
10/126 G Ha I J K L M
Vi poly-L-lysine 1 6 6 6 6 6 6 6 6
2 6 6 6 4 6 3 6 5
3 6 6 ntb 6 6 1 6 5
4 3 3 3 3 2 3 3 2
5 6 5 6 5 6 1 6 6
6 3 3 3 3 3 3 3 3
7 6 6 6 5 5 0 5 6
8 5 5 5 5 5 5 5 5
9 5 5 5 4 4 3 4 4
10 3 3 3 3 3 2 3 3
VaccZyme 1 6 3 6 6 6 6 5 6
5 3 3 3 3 3 3 3 3
6 6 6 6 6 6 5 6 6
Biotinylated-Vi 6 6 6 6 6 6 5 6 6
a : Coded duplicate of IS 16/138.
b : not tested.
Table 4
Intra-laboratory variation for potency estimates of study samples in the VaccZyme, Vi poly-L-lysine and biotinylated-Vi ELISAs.
ELISA Laboratory code Intra-laboratory variation for study samples as % GCVa
10/126 G Hb I J K L M
Vi poly-L-lysine 1 5 6 6 9 7 9 6 9
2 18 15 12 6 20 22 16 23
3 6 10 ntc 12 8 ncd 8 7
4 22 27 9 12 ncd 42 44 ncd
5 12 27 10 11 16 ncd 28 10
6 9 8 11 21 9 15 25 2
7 12 25 22 51 29 ncd 47 22
8 5 10 12 3 6 5 8 6
9 17 12 12 10 14 10 13 13
10 7 8 10 16 11 ncd 17 2
VaccZyme 1 10 9 8 10 8 7 8 6
5 18 14 2 5 25 59 41 32
6 5 6 3 5 2 2 5 5
Biotinylated-Vi 6 5 5 2 7 8 2 4 4
a Geometric Coefficient of Variation.
b Coded duplicate of IS 16/138.
c Not tested.
d Not calculated as fewer than 3 valid potency estimates were obtained for the sample.
Table 5
Causes of assay invalidity in Vi-PLL ELISA.
Invalidity reason Number of invalid cases
Non-parallel (slope ratio < 0.80) 26a
Non-parallel (slope ratio > 1.25) 7
10/126 low (<72.7 IU mL−1) 2
10/126 high (>163.5 IU mL−1) 4
10/126 non-parallel (slope ratio < 0.80) 0
10/126 non-parallel (slope ratio > 1.25) 0
Sample H low (<66.7 IU mL−1) 0
Sample H high (>150 IU mL−1) 4
H non-parallel (slope ratio < 0.80) 1
H non-parallel (slope ratio > 1.25) 2
No convergence (cannot fit model) 4
Poor plate precision (wide CI) 3
Total of invalid cases 53 (out of 474b)
a 21 out of 26 cases are for sample K in the Vi-PLL-ELISA by labs 2, 3, 5 and
7.
b Maximum number of potency estimates possible in this study.
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for samples G, I and J, respectively; n = 2), showing good agreement
with the optimum GM values obtained in this study (47, 28 and 70 IU
mL−1 for samples G, I and J, respectively; n = 3; Table 8).
3.3. Biotinylated Vi ELISA
The biotinylated Vi ELISA performed by laboratory 6 gave valid
estimates of potency relative to IS 16/138 for all samples (Tables 4 and
6), with low levels of intra-laboratory variation (GCV≤8%; Table 5).
However, the ranking of samples G, I and J based on the geometric
mean potencies differed from that obtained by the Vi-PLL and Vacc-
Zyme ELISAs (Table 6 and Fig. 3). Indeed, potency estimates obtained
in the previous study for these study samples, then coded as B, D and E,
by the same biotinylated Vi ELISA were ranked similarly and did not
agree with values obtained by the VaccZyme ELISA [19]. The results of
the current study again confirm a low level of concordance between the
biotinylated Vi ELISA and the VaccZyme or Vi-PLL ELISAs [19].
4. Discussion
The aim of the current study was to evaluate the performance and
reproducibility of a standardised Vi-PLL ELISA alongside the commer-
cial VaccZyme ELISA by multiple laboratories. Only participant 6 used
their in-house ELISA to test study samples, and thus the emphasis of the
current study remains on the comparison of the performance of the Vi-
PLL ELISA and the VaccZyme ELISA. The Vi-PLL ELISA has several
advantages over the VaccZyme ELISA, in that its procedure is published
in the public domain [24,26,27], it uses publicly available biologicals of
standardised quality, its availability is not limited to a single source and
it is less costly to run. Disadvantages are the lower level of standardi-
zation of reagents and the absence of assay specific run controls.
Two participants of the previous study, represented here by la-
boratory codes 1 and 8, submitted a superior dataset from the Vi-PLL
ELISA, which was their in-house ELISA at the time of the previous study
[19]. Both participants produced results with low intra-laboratory
variability and consistently reported high numbers of valid estimates
(see Tables 3 and 4). Indeed, a post-study questionnaire (results not
shown) confirmed that participants adhered closely to the Vi-PLL ELISA
Fig. 2. Overview of slope ratios of samples 10/126 and G-M relative to IS 16/138 when tested in the Vi-PLL ELISA and Vacczyme ELISA. Sample H is a coded
duplicate of 16/138.
Table 6
Geometric mean potency estimates of study samples relative to IS 16/138 in the VaccZyme, Vi poly-L-lysine and biotinylated-Vi ELISAs.
ELISA Laboratory code GMa potency estimates for study samples in IU mL−1
10/126 G Hb I J K L M
Vi poly-L-lysine 1 95 46 98 29 70 10 372 12
2 97 37 96 57 47 43 134 19
3 108 47 ntc 34 68 ncd 329 15
5 130 62 115 28 74 ncd 445 18
6 131 80 112 21 50 10 175 14
8 98 49 105 22 72 14 384 17
9 126 47 125 28 99 32 407 17
10 150 75 114 38 59 ncd 220 16
VaccZyme 1 89 33 84 22 57 9 307 11
6 111 42 100 27 69 11 365 15
Biotinylated-Vi 6 149 131 101 10 40 11 208 11
a Geometric Mean.
b Coded duplicate of IS 16/138.
c Not tested.
d Not calculated as < 3 valid potency estimates were obtained for sample.
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procedure, and that familiarity with the Vi-PLL ELISA was the most
important factor for achieving low intra-laboratory GCVs. A similar
observation can be made for participant 6, a national reference la-
boratory, which performed their in-house Vi-biotinylated ELISA to a
higher standard than the Vi-PLL ELISA, which was introduced in this
laboratory as part of the current study. Participants 1, 2, 3, 5, 6, 8, 9
and 10 produced Vi-PLL ELISA data that were acceptable by our cri-
teria. However, relative potency estimates produced by laboratory 2
showed the lowest concordance within this group. The cause of this
discrepancy is unclear.
Potency estimates in the Vi-PLL ELISA produced by participants 4
and 7, and by participant 5 in the VaccZyme ELISA were less convin-
cing, with several high GCV values (>40%) and a low number of valid
estimates (see Tables 3 and 4). We speculate that in these cases limited
experience with the two ELISA procedures may have played a part. We
note that by criteria less stringent than used in our study these results
may well be acceptable for routine serology.
Exclusion of the relative potency estimates from laboratories 2, 4
and 7 resulted in a high level of concordance between the Vi-PLL and
VaccZyme ELISAs and confirmed the status of sample K as an outlier
(see Table 8 and Fig. 4a and b). We also observed a good agreement
Fig. 3. Geometric mean potency estimates for study samples relative to IS 16/138 in IU mL−1 for the VaccZyme ELISA performed by laboratories 1 and 6, the Vi poly-
L-lysine ELISA (Vi-PLL) performed by laboratories 1, 3, 5, 6, 8, 9 and 10, and biotinylated-Vi ELISA performed by laboratory 6.
Table 7
Concordance correlation coefficients in laboratory pairs for log potencies relative to IS 16/138 in the VaccZyme and Vi poly-L-lysine ELISAs.
Table 8
Summary of overall geometric mean potency estimates of study samples re-
lative to IS 16/138 in the VaccZyme and Vi poly-L-lysine ELISAs.
Data From Vi poly-L-lysine ELISA VaccZyme ELISA
Laboratories 1, 3, 5,
6, 8, 9 and 10
Laboratories 1, 3 and 8 Laboratories 1 and 6







10/126 118 17 7 100 7 3 99 17 2
G 56 26 7 47 <1 3 37 18 2
Hc 111 8 6 101 3 2 92 12 2
I 28 22 7 28 22 3 25 14 2
J 69 22 7 70 <1 3 63 15 2
K 15 48 4 12 23 2 10 16 2
L 318 40 7 361 8 3 335 13 2
M 16 14 7 15 18 3 13 21 2
a Geometric Mean.
b Inter-laboratory Geometric Coefficient of Variation.
c Coded duplicate of IS 16/138.
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Fig. 4. a Comparison of overall geometric mean potency estimates in IU mL−1 relative to IS 16/138 by the Vi poly-L-lysine ELISA performed by laboratories 1, 3, 5, 6,
8, 9 and 10 and the VaccZyme ELISA performed by laboratories 1 and 6. 4b: Comparison of overall geometric mean potency estimates in IU mL−1 relative to IS 16/
138 by the Vi poly-L-lysine ELISA performed by laboratories 1, 3 and 8 and the VaccZyme ELISA performed by laboratories 1 and 6.
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with the relative potencies assigned to coded samples reported in the
previous study [19].
Thus, despite most of the participating laboratories not being fa-
miliar with the Vi-PLL ELISA, a satisfactory performance was achieved
in most cases, with good repeatability and reproducibility observed in
the study results across the majority of laboratories. Concordance in the
relative potency estimates obtained by the Vi-PLL ELISA and the
VaccZyme ELISA was also evident for the panel of samples tested.
We conclude that this study demonstrated that the Vi-PLL ELISA is a
credible alternative to the VaccZyme ELISA, provided operators are
trained and competent, that criteria for reagent quality, for example the
use of high molecular weight PLL, are adhered to, that an appropriate
reference standard is used, and that assay validity criteria (system and
sample suitability criteria) are applied. These measures should enable
an optimal performance of the Vi-PLL ELISA. To minimise intra-la-
boratory variation, it is recommended that a dose response curve of an
in-house reference standard calibrated in IU relative to the 1st WHO IS
for anti-Vi IgG (human) is included in each run. With such an approach
the Vi-PLL ELISA should aid the harmonisation of clinical trial studies
with different TCV formulations and allow comparison of serology data
from different target groups.
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